dhfr and dhps genotype and sulfadoxine‐pyrimethamine treatment failure in children with falciparum malaria in the Democratic Republic of Congo

Open Access
Publisher Website
Google Scholar
Abstract
Summary: Objective  To determine the relationship between mutations in dhfr and dhps and SP treatment failure in Plasmodium falciparum malaria in the Democratic Republic of the Congo (DRC).Methods  Therapeutic efficacy trial was conducted in Rutshuru, Eastern DRC, between June and September 2002, comparing sulfadoxine‐pyrimethamine (SP), SP plus amodiaquine (AQSP) and artesunate plus SP (ASSP) regimens for treating malaria in children under 5 years old. We genotyped 212 samples for mutations associated with SP resistance and investigated their association with treatment failure.Results  In the SP arm, 61% of the subjects experienced treatment failure after 14 days. The failure rate was lower in the combination arms (AQSP: 32%, ASSP: 21%). The dhfr‐108 and dhfr‐51 mutations were nearly universal while 89% of the samples had at least one additional mutation at dhfr‐59, dhps‐437 or dhps‐540. Dhps mutations had a bigger impact on treatment failure in children with high parasite density: for children with a parasite density 45 000 parasites/μl, the treatment failure risk was 58% and 8% for children with both mutations or neither mutation, respectively (RD = 51%, 95% CI: 34%, 67%).Conclusions  Dhps‐437 and dhps‐540 are strongly associated with SP treatment failure and should be evaluated further as a method for surveillance of SP‐based therapy in DRC.

This publication has 28 references indexed in Scilit: